PCSK9 Forum
Click here to invite colleagues
to join the Forum for FREE
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
PCSK9 eBook
New edition of free handbook - fully updated

A lot has happened in the last six months so to help you stay up-to-date about this exciting new therapeutic approach download your free copy of this important introductory guide to the biology and therapeutic value of PCSK9 inhibition. The global experts of the PCSK9 Education and Research Forum have fully updated this popular e-book with summaries of recent research and results of the latest clinical trials.
The new edition includes:

Continuing burden of death and disability from high LDL cholesterol
  • Circulatory diseases remain the leading cause of death in the developed world
  • LDL cholesterol remains the key target of lipid-modifying therapy
  • Familial hypercholesterolaemia and the lifetime burden of elevated LDL cholesterol
Limitations of current management of patients at high cardiovascular risk due to elevated LDL cholesterol
  • The challenge of familial hypercholesterolaemia
  • Low rates of LDL cholesterol goal attainment in other populations at elevated cardiovascular risk
  • Variable LDL cholesterol responses and non-adherence to statins
  • The problem of intolerance of statins
  • Summary of unmet needs in the management of hypercholesterolaemia
PCSK9 inhibition as a strategy for addressing unmet needs in the management of cardiovascular risk
  • PCSK9, the LDL receptor and plasma cholesterol
  • What is PCSK9 and how does it influence circulating levels of LDL cholesterol?
Clinical experience with PCSK9 inhibitors in the management of high LDL cholesterol and cardiovascular risk
  • PCSK9 inhibitors in advanced clinical development
  • Marked reductions in LDL cholesterol and other atherogenic lipoproteins
  • Cardiovascular outcomes trials in progress
  • Preliminary outcomes data for PCSK9 inhibitors
Tolerability and safety of PCSK9 inhibitors

Conclusions: potential role for PCSK9 inhibition in cardiovascular care
PCSK9 Inhibition Handbook
The book is freely available to all healthcare professionals registered with the Forum

Read online »
Download now »
Forward to colleagues »
Not a member?

Register now for free »
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.